Subscribe
Close
  • Free for qualified executives and consultants to industry

  • Receive quarterly issues of Area Development Magazine and special market report and directory issues

Renew

RoosterBio Expands Frederick, Maryland, Operations Campus

12/19/2019
RoosterBio Inc., a cell manufacturing platform technology company focused on accelerating the development of a sustainable regenerative medicine industry, expanded its facility in Frederick, Maryland.

The addition of 5,000 square feet to its existing 15,500 footprint supports the company’s expansion efforts and provides infrastructure to meet a growing international demand for its standardized hMSC bioprocess tools. The company is a leading supplier of human mesenchymal stem/stromal cell working cell banks and hMSC bioprocess systems.

RoosterBio reported its headquarters at The Offices at Westview serves as a center of excellence, incorporating the latest scale up bioprocessing technology and allows the company to quality test its cells and media in a variety of conditions and applications. The new space will increase shipping capabilities for a growing international network by the end of the year.

RoosterBio announced the first expansion of its facility earlier this year which served as a catalyst for its strategic international growth initiatives. The company plans to launch an international presence in Asia during the first half of 2020.

According to company officials, by strengthening its cell manufacturing solution portfolio and presence in the Asia Pacific and Europe, RoosterBio is giving more people around the world the ability to advance regenerative medicine cures.

“Our team has been working diligently this year to grow our customer base across the globe, now shipping to 26 countries and the need to expand our facility is a result of the industry validating our value proposition,” said RoosterBio’s CEO Margot Connor. “As our efforts have increased, we’ve increased our employee base by nearly 30% this year and we’re excited about our continued annual growth rate.” Connor added, “We’re taking RoosterBio to the next level in the international hMSC marketplace.”

Company officials explained, these enhancements build on RoosterBio’s proven track record of industrializing the supply chain for the new field of regenerative medicine. The products that RoosterBio has commercialized are designed to standardize hMSC manufacturing with consistent cGMP product offerings, removing years of time, and millions of dollars, from traditional mesenchymal cell therapeutic product development and clinical translation efforts. RoosterBio said it will also be launching a cGMP version of its extracellular vesicle production tools in early 2020.

Share

Exclusive Research